Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
08 aug 2014 - 07:30
Statutaire naam
Galapagos NV
Titel
Galapagos cash position of €232 M provides solid basis for R&D pipeline investment
Bericht
Net profit of €56 M for first half 2014
Solid cash balance of €232 M on 30 June 2014, liquid assets position of €240 M
Group revenues €63 M, including €18 M revenues from discontinued service operations
Operating loss of continuing operations €15 M, reflecting planned increase in pipeline investment
Group net profit €56 M, resulting from €68 M net gain on sale of service operations
Mature clinical pipeline with multiple Phase 1 and 2 readouts expected over next 18 months
Non-cash revision to full year revenue guidance: now €100 M, including €18 M from discontinued service operations
Guidance for year end 2014 cash position increased to €175 M (was €170 M)
GSK stops development of GSK2586184 in psoriasis and ulcerative colitis, explores other indications
Datum laatste update: 01 september 2024